Abstract: Disclosed are glucose-sensitive nanoparticles which includes a phenylboronic acid derivative and a biocompatible polymer, and is prepared as an amphiphilic conjugate having chemical binding between the phenylboronic acid derivative and the biocompatible polymer. The use of the composition can effectively collect glucose in the cancer tissue, thereby simultaneously performing diagnosis and therapy of cancer.

Abstract: A sensor device (1) for detecting the presence of a target molecule (20) in a sample, is disclosed. The sensor device comprises a measurement sensor (2) comprising a first moiety (16) for forming a binding couple with a first further moiety comprising the target molecule (20) and a detectable label (40) and a reference sensor (3) comprising a second moiety (50) for forming a further binding couple with a second further moiety comprising a further detectable label (40?).

Abstract: Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects.

Abstract: A device for rapid detection of cerebrospinal fluid in a sample fluid, the device uses a sample pad with sensors for detecting the presence of one or more analytes in the sample fluid and an analyzer operatively connected to the sample pad, for quantitative analysis of one or more analytes. A display unit operably connected to the analyzer, for displaying an output of the analysis may also be a part of the device, wherein the display unit may be able to indicate presence or absence of cerebrospinal fluid leakage using an indicator.

Abstract: Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery.

Abstract: A stimulus-responsive gel material includes: a first polymer containing an OH group and having a network structure; a second polymer having a phenylboronic acid structure; fine particles having an average particle diameter of 10 nm or more and 1000 nm or less; and a solvent, wherein a polymer chain of the second polymer penetrates into the network of the first polymer.

Abstract: A method for detecting B. burgdorferi antigens in body fluid samples, such as urine. Polyclonal antibodies are used that bind to 31, 34, and 39 kDa B. burgdorferi antigens, wherein the polyclonal antibodies function as immobilized capture antibodies. Detection antibodies are used, having an enzyme linked thereto, which also bind to the B. burgdorferi antigens. A body fluid sample is reacted with the detection antibodies to form complexes between the detection antibodies and the B. burgdorferi antigens in the body fluid sample. The complexes are reacted with the immobilized capture antibodies, wherein the complexes become linked to the capture antibodies. A substrate is added to the complexes linked to the capture antibodies, wherein the substrate is converted by the enzyme to a visual and/or detectable product if B. burgdorferi antigens are present in the body fluid sample.

Abstract: Polymer particles are provided which contain fluorescent molecules with high presence ratio in a polymer layer thereof and a method for preparing thereof. Polymer particles are swelled in a non-aqueous solution excluding exclusively water preferably promotes selling of the polymer layer and transfer of the fluorescent molecules to the polymer layer could not protected by water molecules such that much more fluorescent molecule may be introduced into inside of the polymer layer. Furthermore, since the water is added to the reaction system prior to evaporation removal of the non-aqueous solvent, dry-up of the polymer particles is prevented by the water remained in the reaction system and the polymer particles including fluorescent molecules with high presence ratio of the fluorescent molecules preferably keep high dispersibility using the above described procedures.

Abstract: Disclosed is a hemolysis reagent composition for the quantitative analysis of glycated hemoglobin (HbAlc) via an enzymatic method. The hemolysis reagent compositions of the present invention containing a zwitterionic surfactant and a nitrous compound considerably accelerate hemolysis rate due to the presence of the zwitterionic surfactant, and also induce the N-terminal ?-chain of hemoglobin released by hemolysis to be exposed to the outside of the hemoglobin molecule and assists the participation of a greater number of molecules in the reaction, thereby improving reaction sensitivity and reaction rate of the glycated hemoglobin, and the nitrous compound makes the protein structure of the hemoglobin flexibly modified so that the amino acid sequence of the N-terminal ?-chain of hemoglobin can be readily cut off, thereby significantly reducing the entire time required for the measurement and improving the accuracy of the measurement.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract: Sensors for target entities having functionalized thereon, at least one aptamer specific to the target entity, and methods of making and using the same are described for use in glycated protein monitoring and/or biomarkers.

Abstract: The invention relates to a device in which molecules capable of reacting with analytes that are to be detected are immobilized on a surface such that said analytes are bound and can be detected in a subsequent reaction or in several reaction steps. According to the invention, at least two such surfaces are combined in a graphically connected manner, one of said surfaces being used for detecting an analyte and the other one being used for verifying or quantifying the analyte. Said surfaces are embodied so as to simultaneously enter into contact with a sample matrix. The inventive device and a corresponding method can be used for all diagnostic areas, especially in medical diagnostics such as diagnoses of allergies, infections, typifications, DNA/RNA diagnoses, pharmacological and toxicological diagnoses, as well as in food diagnostics, veterinary diagnostics, or environmental diagnostics.

Abstract: The method according to the invention consists in providing a wafer having a bottom layer, a top first sacrificial layer and an insulating layer, structuring the first sacrificial layer to form a three dimensional structure onto which a first structural layer is deposited to define a corresponding three dimensional structure on the bottom surface of the first structural layer. The method consists also in forming a second three dimensional structure on the upper surface of the first structural layer.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract: A method and apparatus for the manipulation of colloidal particulates and biomolecules at the interface between an insulating electrode such as silicon oxide and an electrolyte solution. Light-controlled electrokinetic assembly of particles near surfaces relics on the combination of three functional elements: the AC electric field-induced assembly of planar aggregates; the patterning of the electrolyte/silicon oxide/silicon interface to exert spatial control over the assembly process; and the real-time control of the assembly process via external illumination. The present invention provides a set of fundamental operations enabling interactive control over the creation and placement of planar arrays of several types of particles and biomolecules and the manipulation of array shape and size. The present invention enables sample preparation and handling for diagnostic assays and biochemical analysis in an array format, and the functional integration of these operations.

Abstract: A first device comprising a first organic light emitting device (OLED) is described. The first OLED includes an anode, a cathode and an emissive layer disposed between the anode and the cathode. The emissive layer includes a phosphorescent emissive dopant and a host material, that includes nanocrystals. The phosphorescent emissive dopant is bonded to the host material by a bridge moiety.

Abstract: The present application relates to: a strip for lateral flow assay, comprising a support, a medium for development, a sample pad comprising a subpad, and an absorption pad; and a cartridge for lateral flow assay, comprising the same. According to the present application, the strip adopts a novel sample loading method, thereby obtaining reproducible results irrespective of the volume of an injected sample, and it is possible to readily change the amount of a sample, as necessary, thereby improving the reproducibility of measured results and convenience.

Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.

Abstract: The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Abstract: A detection/determination kit with which a substance to be detected or the amount thereof can be rapidly, inexpensively, and easily detected or determined; and a detection/determination method. The kit, which is for detecting a substance to be detected (50) contained in a specimen, comprises: a first compound (10) comprising a first substance including a stimulus-responsive polymer (11) and, bonded to the first substance, a first antibody (13) against the substance (50); and a second compound (20) comprising a second substance (21) which is hydrophilic and, bonded thereto, a second antibody (23) against the substance (50). The first antibody (13) and second antibody (23) can simultaneously combine with the substance (50) at different sites in the substance (50).

Abstract: The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Abstract: A method for preparing a sample by utilizing a shearing force in the presence of a size stabilizer to break apart the sample to obtain nucleic acid molecules in a usable size range. Once nucleic acid molecules are obtained, magnetic nanoparticles are used to concentrate and clean the nucleic acid molecules for further testing.

Abstract: Disclosed herein are methods of accurately measuring carcinoembryonic antigen in a biological sample and methods of identifying and treating a mucinous cyst in a subject.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

Abstract: Disclosed are a pulse laser generator and an optical fiber sensor system using the same. The optical fiber sensor system includes a main optical coupler that receives pulse laser light generated from a pulse laser generator from a first input terminal, branches the light to first and second output terminals to output, and outputs, through a third output terminal, light input reversely from the first and second output terminals, a reference optical fiber that is connected to the first output terminal, a multi-point sensing optical fiber unit that is connected to the second output terminal, and in which optical fibers are connected in series or in parallel corresponding to a plurality of sensing points, an optical detection unit that is connected to the third output terminal, and a diagnosis processing unit that detects a change of the physical quantity for the sensing points from signals from the optical detection unit.

Abstract: Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength ?1, to generate a second wavelength ?2 of radiation having a higher energy than the first wavelength ?1.

Abstract: A measurement system and method for operating a measurement system is disclosed for an analyte determination. The system includes an analysis unit, which is configured to determine a measured analyte value for a body fluid specimen that is applied, a fingerprint sensor, which is configured to detect fingerprint sensor signals for one or various users, and a control unit, which is connected to the analysis unit and the fingerprint sensor unit for data transmission. The control unit is configured to perform a user identification using the detected fingerprint sensor signals and after successful user identification to enable a determination of a measured analyte value with the analysis unit for an identified user. The control unit is additionally configured to analyze the detected fingerprint sensor signals and optionally additional detected fingerprint sensor signals in addition to the user identification in order to provide control signals for performing additional measurement system functions.

Abstract: Methods, devices, and kits for measuring multiple analytes in a sample having a broad range of concentrations using optical diffraction are disclosed. Devices, methods, and kits useful for monitoring and diagnosing diabetes, cardiovascular disease, thyroid disease, hormone-related conditions, and sepsis are also described.

Abstract: This disclosure describes microfluidic devices that include one or more magnets, each magnet being operable to emit a magnetic field; and a magnetizable layer adjacent to the one or more magnets, in which the magnetizable layer is configured to induce a gradient in the magnetic field of at least one of the magnets. For example, the gradient can be at least 103 T/m at a position that is at least 20 ?m away from a surface of the magnetizable layer. The magnetizable layer includes a first high magnetic permeability material and a low magnetic permeability material arranged adjacent to the high magnetic permeability material. The devices also include a microfluidic channel arranged on a surface of the magnetizable layer, wherein a central longitudinal axis of the microfluidic channel is arranged at an angle to or laterally offset from an interface between the high magnetic permeability material and the low magnetic permeability material.

Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.

Abstract: Methods for determining an analyte in a sample by immunoassay in a one-step format without performing washing steps are described. The method includes a first analyte-specific receptor that contains at least two binding sites for the analyte, and a second analyte-specific receptor that selectively binds to an aggregate arrangement of at least two analyte molecules bound to the first receptor.

Abstract: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: A method of immobilizing a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the metal complex is selected to provide a stable binding interaction between the target molecule and the substrate.

Abstract: A method and test strip for detecting one or more analytes in a test solution. The method and test strip include a detectable component, such as a gold particle, that is linked to a binder, such as an antibody, through a linkage. The linkage can include an antibody binding protein and an antispecies antibody.

Abstract: A diagnostic assay system including a test device and a scanning device are described. In one implementation, the scanning device includes a source of electromagnetic radiation, an optics assembly, a detector, and a microprocessor disposed within a chassis. The test device and scanning device may be configured to be movable relative to each other during operation of the scanning device.

Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.

Abstract: A biological fluid sample analysis cartridge is provided that includes a collection port and a body. The body has one or more internal channels in selective fluid communication with the collection port. The collection port includes a collection bowl, and a slide valve assembly operable to be selectively positioned in an open position and a closed position. In the open position, the collection bowl is accessible for sample deposition, and in the closed position the collection bowl is inaccessible for sample deposition.

Abstract: The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of myasthenia gravis.

Abstract: The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

Abstract: The present invention generally relates to stimuli-responsive drug carriers and methods for making. More specifically, the present invention relates to stimuli-responsive lidded particles that respond to a physiological stimulus and dissolve at a target site inside the body thereby releasing therapeutic agents. The present invention further relates to solid, drug-loaded particles that are made from biodegradable polymers. The present invention further relates to methods for fabricating lidded particles and particles for drug delivery.

Abstract: Electrochemiluminescent technique and device suitable for cheap analytical and diagnostic applications, with electrodes manufactured from carbon paste and terbium chelates as labeling compounds.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: A kit for determining for a female subject the implantation potential of embryos obtained or to be obtained by assisted fertilization is described. The kit includes at least one reagent suitable for detection of levels of FF G-CSF or FF G-CSF mRNA, such as anti-G-CSF antibody or a nucleic acid probe for detection of levels of G-CSF mRNA. The kit may also include a set of concentration standards of FF G-CSF and aspirator tips for removing an oocyte and follicular fluid.

Abstract: A system for inserting reagent or macrobeads into bores of a sample plate is disclosed comprising an insertion device arranged to retain one or more reagent or macrobeads by means of a vacuum whilst inserting the reagent or macrobeads into bores of the sample plate.

Abstract: The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. A plurality of smaller flow cells is employed, each with a relatively small area to be imaged, in order to provide greater flexibility and efficiency.

Abstract: A method for high throughput discovery of proteins fluorescently labeled at a cysteine residue and that undergo a change in fluorescence ratio at 2 wavelengths upon binding an unbound analyte is described. Probes are disclosed which are labeled at a cysteine residue and also probes labeled at both cysteine and lysine with two different fluorophores. These probes are useful for characterization and measurement of hydrophobic species in a fluid sample, particularly characterization and measurement of levels of unbound free fatty acids. A profile of unbound free fatty acids can be determined for an individual which can be used to determine the individual's relative risk for disease.

Abstract: Described herein are systems and methods for extending the dynamic range of assay methods and systems used for determining the concentration of analyte molecules or particles in a fluid sample. In some embodiments, a method comprises spatially segregating a plurality of analyte molecules in a fluid sample into a plurality of locations. At least a portion of the locations may be addressed to determine the percentage of said locations containing at least one analyte molecule. Based at least in part on the percentage, a measure of the concentration of analyte molecules in the fluid sample may be determined using an analog, intensity-based detection/analysis method/system and/or a digital detection/analysis method/system. In some cases, the assay may comprise the use of a plurality of capture objects.

Abstract: An apparatus comprises: a sensing element formed on a buried oxide layer of a substrate and providing communication between a source region and a drain region; a gate dielectric layer on the sensing element, the gate dielectric layer defining a sensing surface on the sensing element; a passive surface surrounding the sensing surface; and a compound bound to the sensing surface and not bound to the passive surface, the compound having a ligand specifically configured to preferentially bind a target molecule to be sensed. An electrolyte solution in contact with the sensing surface and the passive surface forms a top gate of the apparatus.

Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Abstract: The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.